GLP-1 Receptor Agonists Versus DPP-4 Inhibitors and Incident Dementia Risk in COVID-19 Survivors with Type 2 Diabetes: A Target Trial Emulation Study.
Drug design, development and therapy · 2026
Abstract e pubblicazione originale
L’abstract è consultabile nella fonte originale. Non viene ripubblicato qui perché non risulta verificata una licenza compatibile.
Leggi nella fonte originale ↗Parole chiave
HumansDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsCOVID-19Dipeptidyl-Peptidase IV InhibitorsDementiaHypoglycemic AgentsMaleFemaleAgedMiddle AgedIncidenceSurvivorsCOVID-19 survivorsDPP-4 inhibitordementiaglucagon-like peptide-1 receptor agonisttarget trial emulationtype 2 diabetes mellitus
Come citare questo studio
Kuo-Chuan Hung, Ting-Sian Yu, Ping-Hsin Liu, Yi-Chen Lai, I-Wen Chen. (2026). GLP-1 Receptor Agonists Versus DPP-4 Inhibitors and Incident Dementia Risk in COVID-19 Survivors with Type 2 Diabetes: A Target Trial Emulation Study.. Drug design, development and therapy. DOI: 10.2147/dddt.s638249
Consulta la pubblicazione originale ↗